smithkline beecham the anglous pharmaceuticals and consumer products group is to create a partnership with marion merrell dow to develop and market overthecounter otc nonprescription medicines in the us the new group would have had sales last year of dollars 660m pounds 3455m and operating profits of dollars 120m making it the fifth largest otc group in the us smithkline beechams shares closed down 7p at 455p smithkline beecham will initially own 90 per cent and marion merrell dow 10 per cent of the partnership smithkline beechams american otc sales last year were about dollars 550m while marion merrell dows were dollars 111m the aim is a 5050 arrangement as new products are licensed the companies said they were committed to similar cooperation in other countries mr john ziegler north american president of smithkline beecham consumer brands will lead the partnership mr bob bauman the anglous groups chief executive said when smithkline beecham was created we said our vision was to achieve leadership in healthcare and in each of our four business segments he added that the partnership with marion merrell dow was another step towards achieving this goal both groups have prescription products that could be marketed by the new group smithkline beecham has asked the us food and drug administration fda for an otc licence for tagamet the antiulcer drug whose patents run out in 1994 it had worldwide sales last year of more than dollars 1bn marion merrell dow said it might seek otc licences for seldane an antihistamine and the antismoking products nicorette and nicoderm nicoderm which uses a transdermal patch was launched in 1991 and had sales of dollars 137m during the first six months of this year the deal is rather imprecise said mr jonathan de pass pharmaceuticals analyst at bzw it all depends on whether they receive fda approval for seldane and tagamet and whether they successfully extend the relationship worldwide if they do the implications are enormous safety concerns about the new partnerships seldane and tagamet may delay or prevent fda approval seldane is potentially dangerous to patients with a damaged liver or those taking two other drugs ketoconazole an antifungal treatment and erythromycin an antibiotic there are also fears that patients with stomach cancer could misdiagnose an ulcer and buy tagamet